期刊文献+

UPLC-MS/MS法检测大鼠血浆中阿法替尼浓度及其药动学研究 被引量:2

Determination and Pharmacokinetic Study of Afatinib in Rat Plasma by UPLC-MS/MS
下载PDF
导出
摘要 目的:建立一种检测大鼠血浆中阿法替尼浓度的UPLC-MS/MS方法。方法:选择用乙腈沉淀的蛋白质样品进行样品处理并运用Waters XEVO TQD三重四级杆液质联用仪和CORTECS BEH C18柱(50 mm×2.1 mm,1.6μm)分离分析物。流动相由乙腈和水(0.1%甲酸)组成,流速为0.4 ml·min^(-1),柱温为40℃,内标为来那替尼。采用正离子电喷雾多反应监测(MRM)模式对分析物进行定量,目标碎片离子为阿法替尼m/z 486.19→112.1,来那替尼(IS)m/z 557.3→112.15。结果:阿法替尼在1-200 ng·ml^(-1)范围内线性关系良好(r=0.998 1),定量下限为1 ng·ml^(-1)。日内精密度和日间精密度均≤9.51%,阿法替尼从血浆中回收率高于77.1%。大鼠灌胃给药和静脉给药阿法替尼后,t_(1/2)分别为7.19 h和2.69 h,C_(max)分别为97.78 ng·ml^(-1)和123.37 ng·ml^(-1),AUC_((0-∞))分别为1 505.4 ng·h·ml^(-1)和405.55 ng·h·ml^(-1)。结论:该方法准确可靠,操作简便,重复性好,适用于灌胃和静脉注射10和2 mg·kg^(-1)剂量的阿法替尼的药动学研究。 Objective: To establish an accurate and selective UPLC-MS/MS) method for the determination of afatinib in rat plasma. Methods: Protein precipitating by acetonitrile was used to prepare the samples. A CORTECS BEH C18 column( 50 mm×2. 1 mm,1. 6 μm) was used to separate the analytes at 40℃. The mobile phase consisted of acetonitrile and water( 0. 1% formic acid) with the flow rate of 0. 4 ml·min-1. The analytes were quantified by multiple reaction monitoring( MRM) mode with positive electrospray ionization,while the target fragment ions were m/z 486. 19→112. 1 for afatinib and m/z 557. 3→112. 15 for neratinib( IS). Results: The calibration curve obtained good linearity for afatinib within the range of 1 – 200 ng·ml-1( r=0. 998 1),and the LLOQ in rat plasma was 1. 0 ng/ml. The intra-and inter-day precisions were both ≤9. 51%. The recovery of afatinib from plasma was above 77. 1%. After intragastric administration and intravenous administration of afatinib in rats,the t1/2 was 7. 19 h and 2. 69 h,Cmax was 97. 78 ng·ml-1 and 123. 37 ng·ml-1,and AUC( 0-∞)was 1 505. 4 ng·ml-1·h and 405. 55 ng·ml-1·h,respectively. Conclusion: The validated method can be applied in the pharmacokinetic study of afatinib at the intragastric and intravenous dosage of 10 and 2 mg·kg-1,respectively.
作者 汤尘尘 张传香 谭金桃 马丹凤 王双虎 周云芳 Tang Chenchen;Zhang Chuanxiang;Tan Jintao;Ma Danfeng;Wang Shuanghu;Zhou Yunfang(Department of Pharmacy, Children' s Hospital of Hunan Province, Changsha 410007, China;Laboratory of Clinical Pharmacy, People's Hospital of Lishui)
出处 《中国药师》 CAS 2018年第6期977-981,共5页 China Pharmacist
基金 浙江省自然科学基金青年基金项目(编号:LYY18H280003)
关键词 阿法替尼 药动学 超高效液相色谱-质谱/质谱 大鼠 Afatinib Pharmacokinetics UPLC-MS/MS Rat
  • 相关文献

参考文献5

二级参考文献61

  • 1FERLAY J, SHIN HR, BRAY F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 [ J]. lnt J Cancer, 2010,127(12) :2893 - 2917.
  • 2SEQUIST LV, YASIG JCH, YAMAMOTO N, et al. Phase Ⅲ study of afatinib or cisplatin plus pemetrexed in patients with me- tastatic lung adenocarcinoma with EGFR mutations [ J], J Clin Oncol, 2013,31 (27) :3327 - 3334.
  • 3SIBILIA M,KROISMAYR R,LICHTENBERGER BM,et al. The epidermal growth factor receptor: from development to tumorigen- esis [ J ]. Differentiation, 2007,75 ( 9 ) : 770 - 787.
  • 4YUN CH, BOGGON TJ, LI Y, et al. Structures of lung cancer- derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity [ J]. Cancer Cell, 2007,11 (3) :217 -227.
  • 5HIRSCH FR, VARELLA-GARCIA M, CAPPUZZO F. Predic- tive value of EGFR and HER2 over-expression in advanced non- small-cell lung cancer [ J ]. Oncogene, 2009,28 ( Suppl 1 ) : S32 - S37.
  • 6FDA. Afatinib [ EB/OL ]. [ 2014 - 04 - 25 ]. http ://www. ac- cessdata, fda. gov/drugsatfda_docs/label/2013/201292s0011bl. pdf.
  • 7MURAKAMI H, TAMURA T, TAKAHASHI T, et al. Phase Ⅰ study of continuous afatinib (BIBW 2992 ) in patients with ad- vanced non-small cell lung cancer after prior chemotherpy/erlo- tinib/gefitinib( LUX-Lung 4 ) [ J ]. Canver Chemother Pharma- col, 2012,69(4) :891 - 899.
  • 8YAP TA, VIDAL L, ADEMA J, et al. Phase Ⅰ trial of the irre- versible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors [ J ]. J Clin Oncol, 2010,28 ( 25 ) : 3965 - 3972.
  • 9MILLER VA, HIRSH V, CADRANEL J, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy ( LUX-Lung 1 ) : a phase 2b/3 randomised tri.al[ J ]. Lancet Oncol, 2012,13 (5) :528 - 538.
  • 10YANG JCH, SHIH JY, SU WC, et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor muta- tions ( LUX-Lung 2) : a phase 2 trial[ J ]. Lancet Oncol, 2012,13 (5) :539 -548.

共引文献39

同被引文献7

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部